Terray Therapeutics stock
Private-market facts for current and former Terray Therapeutics employees researching their stock.
Overview
Drug discovery company using massively parallel biochemistry on microchip-scale reaction arrays to screen billions of small molecule interactions for novel therapeutics.
Selling Terray Therapeutics shares
Why shareholders consider selling
Shareholders in Terray Therapeutics may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Terray Therapeutics does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Terray Therapeutics stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Terray Therapeutics shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Terray Therapeutics shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series B round can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Terray Therapeutics shareholders
Exploring equity in Terray Therapeutics often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Terray Therapeutics most recently raised a Series B round . Total funding raised to date is approximately $320M.
Lead investors in this round include Andreessen Horowitz and 8VC.
Founders & company background
Terray Therapeutics was founded in 2021 by Jacob Berlin and is headquartered in Pasadena, CA.
Investors
Industry
Similar private companies
Frequently asked questions
- Is Terray Therapeutics still a private company?
- Yes, Terray Therapeutics is currently a private company.
- What is Terray Therapeutics's latest funding round?
- Terray Therapeutics's most recent known round is Series B.
- What is Terray Therapeutics's valuation?
- Terray Therapeutics's valuation has not been publicly disclosed.
- Who are the investors in Terray Therapeutics?
- Notable investors include Andreessen Horowitz, 8VC.
- Can I sell my Terray Therapeutics stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Terray Therapeutics stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Terray Therapeutics data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.